Fuji Pharma Co., Ltd. (TYO:4554)

Fuji Pharma Balance Sheet

Financials in millions JPY. Fiscal year is October - September.

Assets

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022
Cash & Equivalents	9,496	7,245	4,585	2,324	3,546
Cash & Short-Term Investments	9,496	7,245	4,585	2,324	3,546
Cash Growth	31.07%	58.02%	97.29%	-34.46%	-65.23%
Accounts Receivable	20,531	17,987	18,426	16,304	12,527
Other Receivables	454	296	453	216	134
Receivables	20,985	18,283	18,879	16,520	12,661
Inventory	22,559	21,215	18,005	19,371	15,823
Other Current Assets	1,343	1,170	999	899	2,697
Total Current Assets	54,383	47,913	42,468	39,114	34,727
Property, Plant & Equipment	20,360	20,914	20,911	20,547	18,762
Long-Term Investments	6,041	8,308	13,036	14,702	10,211
Goodwill	-	-	88	412	691
Other Intangible Assets	13,692	13,941	12,356	10,081	9,713
Long-Term Deferred Tax Assets	3,810	2,327	1,139	475	1,432
Other Long-Term Assets	1	2	2	1	2
Total Assets	98,287	93,405	90,000	85,332	75,538

Liabilities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022
Accounts Payable	3,709	4,570	4,140	5,672	6,249
Accrued Expenses	1,769	1,105	560	883	990
Short-Term Debt	15,300	15,300	15,300	11,300	8,300
Current Portion of Long-Term Debt	1,898	1,981	7,100	5,210	2,440
Current Portion of Leases	600	582	569	514	377
Current Income Taxes Payable	1,365	963	1,567	484	444
Other Current Liabilities	8,351	6,487	6,561	5,708	5,175
Total Current Liabilities	32,992	30,988	35,797	29,771	23,975
Long-Term Debt	7,054	8,952	1,583	8,683	11,193
Long-Term Leases	3,521	4,122	4,702	3,241	2,259
Pension & Post-Retirement Benefits	2,103	2,215	2,130	1,863	1,766
Other Long-Term Liabilities	167	222	227	598	541
Total Liabilities	45,837	46,499	44,439	44,156	39,734

Shareholders' Equity

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022
Common Stock	5,555	3,904	3,799	3,799	3,799
Additional Paid-In Capital	6,163	4,511	4,406	4,409	4,409
Retained Earnings	37,824	36,219	34,256	29,082	26,546
Treasury Stock	-480	-498	-505	-567	-579
Comprehensive Income & Other	3,384	2,767	3,602	4,451	1,627
Total Common Equity	52,446	46,903	45,558	41,174	35,802
Minority Interest	4	3	3	2	2
Shareholders' Equity	52,450	46,906	45,561	41,176	35,804
Total Liabilities & Equity	98,287	93,405	90,000	85,332	75,538

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022
Total Debt	28,373	30,937	29,254	28,948	24,569
Net Cash (Debt)	-18,877	-23,692	-24,669	-26,624	-21,023
Net Cash Growth	-	-	-	-	-
Net Cash Per Share	-741.32	-970.86	-1014.74	-1095.58	-865.39
Filing Date Shares Outstanding	26.13	24.46	24.31	24.3	24.29
Total Common Shares Outstanding	26.13	24.46	24.31	24.3	24.29
Working Capital	21,391	16,925	6,671	9,343	10,752
Book Value Per Share	2007.35	1917.91	1873.87	1694.21	1473.66
Tangible Book Value	38,754	32,962	33,114	30,681	25,398
Tangible Book Value Per Share	1483.29	1347.85	1362.03	1262.45	1045.42
Order Backlog	-	2,540	1,697	1,672	1,313

Data Source: S&P Global Market Intelligence Last updated: Nov 10, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 15, 2026

Data Sources Report a data error